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 2016 Zika Lessons Learned
 Updates to Zika Guidance
 Task force recommendations 






 Continental US will continue to have travelers who go to 
areas with Zika virus 
 Further local transmission of Zika virus is still a potential; 
however, the extent is unknown
 Zika diagnostic test performance continues to be limited by 
cross-reactivity to other flaviviruses
Why Important – Continental US
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 CDC-developed MAC-ELISA (February 26, 2016) and Trioplex rRT-PCR 
(March 17, 2016) tests receive first FDA EUA to diagnose Zika virus 
infection 
 CDC continues to manufacture and distribute reagents for these assays 
domestically and internationally









Number of Specimens Tested by 
Zika IgM MAC-ELISA
CDC-Atlanta 5,023 3,464 2,827
CDC-Fort Collins 18,262 3,926 15,571




Total 165,2692 77,965 101,762
Updated 1/2017
 Limited data on viral persistence and effect on testing algorithms
 Specificity of diagnostic assays
 In-house evaluation of 3 commercial assays with MAC-ELISA as gold 
standard
 Usefulness of PRNT
 Cross reactivity due to past flavivirus infections
 Turnaround time from sample receipt to when results reach physicians
 Discussions ongoing to pursue Health Level-7 (HL7)messaging to decrease 




InBios (EUA approved) 82% 85%
NovaTec NovaLisa 70% 98%
Euroimmun 72% 95%
 Continue to provide Zika virus subject matter expert and reference 
laboratory support in Fort Collins; surge planning for upcoming season in 
progress 
 Maintain surge laboratories for Zika diagnostic testing in Atlanta
 Assist state and territorial laboratories, as needed
 Refine performance of diagnostic assays inclusive of assessing the value of 
whole blood and urine in molecular diagnostics
 Consider updates to the testing algorithm to allow increased flexibility and 
to simplify as appropriate
 Assist as needed in moving testing to commercial laboratories
 Continue to conduct new research
Zika Virus Laboratory Priorities, 2017
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 Early in response CDC entered into agreements with the 4 nation-wide 
commercial laboratories
 Provided MAC-ELISA reagents free of charge to encourage testing until 
additional serologic assays achieved EUA approval
 Challenges with reporting and commercial lab performance
 Movement of testing will decrease surge needs for CDC laboratories 
 12 PCR assays currently FDA EUA approved (including Trioplex)
 2 IgM assay currently FDA EUA approved (including MAC-ELISA)
Plans - Move testing to commercial laboratories
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 Improve sensitivity of high-throughput rRT-PCR by specimen volume or 
type
 Studies ongoing to evaluate serum, whole blood, and urine to evaluate 
sensitivity of each
 Develop a Zika virus multiplex bead assay (IgM/IgG)
 Investigation of more specific antibodies 
 Develop rapid and specific IgM diagnostic test that uses mass 
spectrometry
 Refine recombinant antigens in testing platforms to eliminate the need for 
inactivation of live virus
Plans - New Research:  Improvement of Molecular and Serologic 
Diagnostic Tools for Zika Virus (all CDC laboratories)
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 Epidemic transmission
 Almost 38,000 confirmed cases (102,000 tested)
 Peak of epidemic during September 2016
 Rate Zika-associated of birth defects will not be known until summer 2017
Why Important – Puerto Rico
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 Likely will start in May
 Likely will be less intense for Zika, but could be high for 
dengue or chikungunya due to varying seasonality
Upcoming Transmission Season – Puerto Rico
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 Existing PR requirement to test pregnant women in each trimester of 
pregnancy (30,000 pregnancies/year)
 Co-circulation of dengue and chikungunya viruses requires complex 
testing algorithm for symptomatic cases
 PRNTs are impractical and uninformative because of the high volumes of 
samples and the previous exposure of the population to dengue
 Confirmatory testing of PCR neg/IgM pos is not feasible
Concerns – Puerto Rico
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 CDC Dengue laboratory (Capacity = 1500 samples/month) to support 
PRDH arbovirus surveillance needs
 Surge Plan for 2017
 Validate and evaluate CDC’s commercial diagnostic tests for Zika and 
provide recommendations to Puerto Rico Department of Health (PRDH)
*BCEL - Biological and Chemical Emergencies Laboratory




CDC-DB (Excedent up to 1500 
samples/week
CDC-ATL (Excedent up to 
500 samples/week
 Supports testing for Zika-related epidemiologic and clinical assessments as 
needed.  For example
 Guillain-Barre Syndrome surveillance
 Screening of pregnant women
 Cross reactivity in serologic tests
 Virus persistence in body fluids
 Testing of placenta or newborns
 Improve automation and throughput for Zika, dengue and chikungunya 
testing







Eddie Ades, Robert Lanciotti, Christy Ottendorfer
Wed 3/15/2017 / 2pm–3pm EDT  - Domestic
Wed 3/15/2017 / 5 pm–6 pm EDT - Islands
Bridge Line: 1(888)972-6716/ Passcode: 6721430
Joint Information Center/Communications
Erin Connelly 
Wed 3/22/2017 / 2pm–3pm / Rm 5116 
Bridge Line: 1(888)972-6716/ Passcode: 6721430
Epidemiology Task Force
Stacey Martin, Carolyn Gould
Thurs 3/23/2017 / 2pm–3pm / Rm 5116 
Bridge Line: 1(888)972-6716/ Passcode: 6721430
Vector Issues Team 
Janet McAllister, Audrey Lenhart
Tues 3/28/2017 / 2pm–3pm / Rm 5116 
Bridge Line: 1(888)972-6716/ Passcode: 6721430
Policy and Partnerships
Sue Visser, Melody Stevens
Wed 3/29/2017 / 1:30pm–2:30pm / Rm 5116 
Bridge Line: 1(888)972-6716/ Passcode: 6721430
Pregnancy and Birth Defects Task Force (including surveillance) 
Peggy Honein, Dana Meaney-Delman, Suzanne Gilboa
Wed 3/29/2017 / 3pm–4pm / Rm 5116 
Bridge Line: 1(888)972-6716/ Passcode: 6721430
Blood Safety Task Force
Sustainment Strategy Discussions
Koo Chung, Matt Kuhnert, Craig Hooper
Thurs 3/30/2017 / 2pm–3pm / Rm 5116 




Thurs 3/30/2017 / 3:30pm–4:30pm / Rm 5116 
Bridge Line: 1(888)972-6716/ Passcode: 6721430
For more information, contact CDC  
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the  
official position of the Centers for Disease Control and Prevention.
Thank You!
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